Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a retrospective analysis at Erasmus University Medical Center found that methotrexate and cyclosporine A may be most effective for lichen planopilaris and cyclosporine A and retinoids for frontal fibrosing alopecia, although side effects were a concern.

This review explores current therapeutic options for frontal fibrosing alopecia, noting the use of finasteride, topical tacrolimus, hydroxychloroquine, and excimer laser in managing the condition, but reports no new clinical results.

This review discusses the potential and varied uses of spironolactone in dermatological conditions such as acne, hidradenitis suppurativa, hirsutism, and female pattern androgenetic alopecia, emphasizing dosage, treatment recommendations, and adverse effects for practical clinical use.

Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.

This study demonstrated that finasteride treatment reduced cardiac dysfunction and hypertrophic remodeling in mice after myocardial infarction, suggesting potential as a therapeutic strategy for heart failure.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

This study found that spironolactone treatment can normalize endothelial function and improve cholesterol levels in non-obese patients with polycystic ovary syndrome.

Minoxidil effectively lowers blood pressure without major side effects.

In this publication, the authors explored whether there is a scientific basis for using lymecycline to treat frontal fibrosing alopecia, but the abstract does not provide study results or conclusions on its efficacy.

In this case report, a 59-year-old man experienced recurrent pericardial effusion linked to minoxidil, with serologic indications of drug-induced lupus erythematosus, underscoring the need for clinicians to consider this rare complication of widespread minoxidil use.

This review found that Tolvaptan is the only drug shown to slow the progression of autosomal dominant polycystic kidney disease, but it does not affect mortality or kidney failure outcomes.

In this study, Ark-e-Kasni was found to alleviate PCOS symptoms in rats by restoring hormonal levels, improving insulin sensitivity, and reducing inflammation and cystic follicles, suggesting its therapeutic potential via diverse molecular mechanisms.

In a rodent study, researchers found that oral phenytoin and spironolactone significantly mitigated 5-fluorouracil-induced hair loss and oxidative stress, suggesting potential therapeutic benefits for chemotherapy-induced alopecia and enhanced recovery.

This review reports that 100 mg/day spironolactone improved hair growth more than placebo and was more effective in reducing hair growth than finasteride and low-dose cyproterone acetate, but its effectiveness for acne remains unclear due to small sample sizes.

In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.

This analysis reports no significant differences between spironolactone and metformin for managing PCOS, noting spironolactone remains a potential off-label option for patients unable to use hormonal contraceptives, but larger studies are necessary to confirm its efficacy.

In this case report, a female patient with frontal fibrosing alopecia and lichen scleroatrophicus vulvae experienced excellent results from hair microtransplants combined with finasteride and topical minoxidil, maintained over six years.

This study suggests that lisinopril's cardiometabolic effects are weaker in men with early-onset male-pattern baldness compared to those with normal hair growth.

Low-dose spironolactone can be effective for treating hair loss in women.

This narrative review explores the failure of fludalanine as an orally active antibiotic and highlights valuable insights into problem-solving strategies in drug discovery, without reporting new clinical results.

In this case report, a 47-year-old man experienced systemic hair loss after starting hemodialysis, which resolved after discontinuing the antipruritic drug nalfurafine, suggesting its role in causing hair follicle capillary regression.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

This study found that finasteride is stable under various stress conditions except for basic hydrolysis at extreme pH levels and identified compatible and incompatible excipients in pharmaceutical formulations, suggesting formulation changes for increased safety.

Spironolactone for skin issues rarely causes low blood pressure.

This article includes no new results; it discusses ongoing treatment approaches for frontal fibrosing alopecia and lichen planopilaris.

Oral cyclosporin doesn't stop hair loss.

In this study, finasteride was found to induce tissue-specific P-glycoprotein activity in the liver and kidney of rabbits after a 14-day treatment period.